Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease
- PMID: 9612114
Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease
Abstract
Background: Disturbed skin microcirculation in patients with peripheral arterial occlusive disease (PAOD) might be affected by prostaglandin E1 (PGE1). The purpose of this study was to investigate local skin perfusion at the forefoot and toe of PAOD patients during different modes of administration of PGE1.
Patients and methods: In 17 patients with severe PAOD local intradermal haemoglobin oxygen saturation (SHB) and dermal vascular reserve capacity, transcutaneous oxygen pressure (tcPO2) and laser Doppler flux (LDF) were determined during intra-arterial (1.5 ng/kg body weight/min) and intravenous (6 ng/kg body weight/min) infusion of PGE1.
Results: SHB significantly increased at both locations during intravenous PGE1; intra-arterial administration significantly increased SHB in the skin of the forefoot only. Reserve capacity increased during intravenous administration and was markedly reduced during intra-arterial infusion. No significant changes were found regarding tcPO2 and LDF.
Conclusions: These data suggest different therapeutic mechanisms for intra-arterial and intravenous administered of PGE1.
Similar articles
-
Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value.Angiology. 1995 May;46(5):357-67. doi: 10.1177/000331979504600501. Angiology. 1995. PMID: 7741319
-
[Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].Vasa Suppl. 1991;33:341-2. Vasa Suppl. 1991. PMID: 1788749 Clinical Trial. German.
-
[Double-blind placebo-controlled study of the behavior of tcPO2 during intravenous infusion of prostaglandin E1 in patients with severe arterial occlusive disease].Vasa Suppl. 1992;35:36-8. Vasa Suppl. 1992. PMID: 1481055 Clinical Trial. German. No abstract available.
-
[Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].Vasa. 2003 Nov;32(4):187-92. doi: 10.1024/0301-1526.32.4.187. Vasa. 2003. PMID: 14694766 Review. German.
-
Recanalization of chronic peripheral arterial occlusions by alternating intra-arterial rt-PA and PGE1.Vasa. 1998 Feb;27(1):20-3. Vasa. 1998. PMID: 9540428 Review.
Cited by
-
Anticoagulative strategies in reconstructive surgery--clinical significance and applicability.Ger Med Sci. 2012;10:Doc01. doi: 10.3205/000152. Epub 2012 Jan 17. Ger Med Sci. 2012. PMID: 22294976 Free PMC article.
-
Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation.AAPS PharmSciTech. 2016 Apr;17(2):409-17. doi: 10.1208/s12249-015-0366-1. Epub 2015 Jul 21. AAPS PharmSciTech. 2016. PMID: 26195071 Free PMC article.
-
Insights into Liposomal and Gel-Based Formulations for Dermatological Treatments.Gels. 2025 Mar 26;11(4):245. doi: 10.3390/gels11040245. Gels. 2025. PMID: 40277680 Free PMC article. Review.
-
Blue Toe Syndrome in Behçet's Disease: A Case Report.Am J Case Rep. 2024 Jun 22;25:e943813. doi: 10.12659/AJCR.943813. Am J Case Rep. 2024. PMID: 38907515 Free PMC article.